Skip to main content

Pertuzumab for Breast Cancer Cleared for EU Approval


Pertuzumab ( Perjeta, Roche) for breast cancer has just been given a go-ahead in the first step of the European approval process.
The drug was given a positive opinion from the Committee of Medicinal Products for Human Use (CHMP), which is a recommendation for marketing authorization. The next step is actual approval from the European Commission.
Pertuzumab was approved in the United States earlier this year, costing approximately $188,000.
The indication for its use is rather narrow. Pertuzumab, a humanized monoclonal antibody directed against HER2, is indicated for use with the first available HER2-targeted agent trastuzumab ( Herceptin, Roche), as well as docetaxel, in patients with metastatic or locally recurrent unresectable HER2-positive breast cancer who have not received previous HER2therapy or chemotherapy for their metastatic disease.
According to the CHMP, the benefits of pertuzumab are its ability to improve progression-free survival, overall survival, and objective response rate, compared with placebo.
These benefits were demonstrated in the phase 3 CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial, first reported at the San Antonio Breast Cancer Symposium in 2011, as reported at the time by Medscape Medical News, and later published in the New England Journal of Medicine(2012;366:109-119).
The most common adverse effects with pertuzumab are diarrhea, alopecia, leucopenia, and febrile neutropenia, the CHMP notes.
The drug is expected to be expensive, which could cause problems with reimbursement in European countries. In the United States, double HER2 treatment with pertuzumab plus trastuzumab costs about $180,000 per course of therapy.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more